ALK and non-small cell lung carcinoma: In a phase I/II clinical trial of alectinib in 47 patients with crizotinib-resistant ALK-positive NSCLC (AF-002JG), the CNS response rate was 77.8% (7/9 patients) in patients with measurable or non-measurable CNS disease at baseline, and the CNS disease control rate was 100% (all nine patients).